RBM38 and ovarian carcinoma: Recent studies have shown that RBM38 is oncogenic and amplified in chronic lymphocytic leukemia [11], ovarian cancer [12], prostate cancer [13,14], etc. Conversely, some studies have demonstrated that RBM38 has a tumor-suppressive effect in colorectal cancer [15], breast cancer [16], non-small cell lung cancer [17], esophageal adenocarcinoma [18], etc. These contradictory results indicate that RBM38 can promote or suppress cancer progression in different tumors by regulating different signaling pathways.